Tanomed has developed a unique nasal spray to relieve and prevent the progression of the common cold by reinforcing the body’s own defenses. The patented technology is based on Swedish research carried out in cooperation with Umeå University and with business development support from the Umeå Biotech Incubator. The company was sold to Karo Bio AB in spring 2015.
We are developing an oral patch, which will be a patented galenic formulation, providing rapid pain relief for the patient. The product can theoretically reach a target patient population of 10-20,000 patients annually in Sweden, and considerably higher in international markets.
A natural compound-approach for neutralizing exotoxins from various gram-negative pathogens. Gobroxia AB has developed a novel method to treat pathogens causing diseases such as diarrhea, sepsis, tooth loss and whooping cough in humans, as well as bovine respiratory disease in cattle and pneumonia in pigs.
Quretech Bio develops innovative antibiotics by stopping bacterial virulence with a first-in-class active substance. The approach is not to kill bacteria, but make them harmless – thus complementing existing treatments and making established antibiotic drugs more effective without causing resistance.
We aim to develop a novel therapeutic for treatment of aggressive prostate cancer. The treatment is intended to improve the quality of life and extend the life expectancy in patients by preventing the formation of metastases. The approach is an antibody that is expected to have fewer side-effects than current treatment options for this indication.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 700 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
Current drugs against mycoses are toxic. We aim to develop a new class of antifungal agents that disarm the invasive forms of fungal cells instead of merely eradicating them. This has two advantages: The new compounds are less aggressive for the host and resistance development is reduced.
Lipum develops a biological pharmaceutical for a novel mechanism of action in the treatment of chronic inflammations. Essentially, the drug will be a monoclonal antibody directed towards the protein bile salt-stimulated lipase, BSSL. One indication is as an orphan drug for the more severe forms of Juvenile Idiopathic Arthritis (JIA), providing patients with an effective treatment alternative having less adverse effects than the drugs used today.
Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.